Sort
10,766 grants matching “checkpoint inhibitor”
Research Project 1: Enhancing neoadjuvant therapy to prevent breast cancer recurrence
$395,341Michael T Lewis · Utah State Higher Education System--University Of Utah · U54 · FY2025 · CA
Small Molecule Activators of Procaspases as Anti-Cancer Agents
$395,217Paul Hergenrother · University Of Illinois At Urbana-Champaign · R01 · FY2022 · CA
Systemic delivery of an oncolytic adenovirus targeting TGFβ to enhance anti-PD-1 and anti-CTLA-4 therapy for triple negative breast cancer
$395,126Weidong Xu · Endeavor Health Clinical Operations · R01 · FY2021 · CA
Project 4 :Using TME genetics and immunobiology to drive combination immunotherapies
$395,115Elizabeth Marion Jaffee · Johns Hopkins University · P50 · FY2022 · CA
Project 4 :Using TME genetics and immunobiology to drive combination immunotherapies
$395,115Elizabeth Marion Jaffee · Johns Hopkins University · P50 · FY2019 · CA
Chemo-sensitizing IDH1-mutated glioma by molecular targeting
$395,001Chun Zhang Yang · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
An In Silico, Medical Record-based Model for Understanding the INitiation of Autoimmune Events (IMMUNE)
$395,000Theresa L Walunas · Northwestern University At Chicago · R61 · FY2019 · AR
A novel dual-carrier ultrasmall nanomedicine for the treatment of stroma-rich pancreatic cancer
$394,967Katherine Marie Eichinger · Duo Oncology Inc · R41 · FY2023 · CA
Targeting the cytokine circuitry of KRAS-driven lung cancer
$394,956David A Barbie · Dana-Farber Cancer Inst · R01 · FY2024 · CA
Platelets-Mediated Delivery of Checkpoint Inhibitors for Post-Surgical Cancer Immunotherapy
$394,916Song Li · University Of California Los Angeles · R01 · FY2023 · CA
Platelets-Mediated Delivery of Checkpoint Inhibitors for Post-Surgical Cancer Immunotherapy
$394,916Song Li · University Of California Los Angeles · R01 · FY2022 · CA
Effects of Complement on the Tumor Microenvironment in Lung Cancer
$394,879Raphael A. Nemenoff · University Of Colorado Denver · R01 · FY2023 · CA
Effects of Complement on the Tumor Microenvironment in Lung Cancer
$394,879Raphael A. Nemenoff · University Of Colorado Denver · R01 · FY2022 · CA
Project 2: Reversing STING-mediated immunosuppression in LKB1-mutant lung adenocarcinoma
$394,856Haian Fu · Emory University · P01 · FY2022 · CA
Regulation of Tumor Microenvironment in Cancer
$394,854Dmitry Isaac Gabrilovich · Wistar Institute · R01 · FY2014 · CA
Spatiotemporal control of insulin signaling by mitotic regulators
$394,800Eunhee Choi · Columbia University Health Sciences · R01 · FY2024 · DK
S100A4 mediated immune suppression in GBM
$394,788Kyuson Yun · Methodist Hospital Research Institute · R01 · FY2025 · NS
Enhancing antitumor efficacy by intratumoral delivering LAIR1 inhibitory signaling
$394,687Jianping Huang · University Of Florida · R21 · FY2025 · CA
Development of Novel Antibody Conjugates for Cancer Immunotherapy
$394,661Weiping Tang · University Of Wisconsin-Madison · R01 · FY2024 · CA
Defining the Function of Age-Related Epimutation in Intestinal Tumorigenesis
$394,591Lanlan Shen · Baylor College Of Medicine · R01 · FY2025 · CA
LAT1 as a Novel Therapeutic Target in Colorectal Cancer
$394,532Subbaya Subramanian · University Of Minnesota · R21 · FY2025 · CA
Targeting Lag-3 and PD -1 in Myeloid Cells of GBM
$394,429Michael Lim · Stanford University · R01 · FY2025 · NS
Project 5: Enhancement of the Anti-Tumor Activity and Targeted Applications of Third Party Donor-Derived EBV-specific T-cells
$394,269Richard J O'Reilly · Sloan-Kettering Inst Can Research · P01 · FY2023 · CA
Project 5: Enhancement of the Anti-Tumor Activity and Targeted Applications of Third Party Donor-Derived EBV-specific T-cells
$394,269Richard J O'Reilly · Sloan-Kettering Inst Can Research · P01 · FY2020 · CA
Project 5: Enhancement of the Anti-Tumor Activity and Targeted Applications of Third Party Donor-Derived EBV-specific T-cells
$394,269Richard J O'Reilly · Sloan-Kettering Inst Can Research · P01 · FY2019 · CA